CN110914271B - 二环酮化合物及其使用方法 - Google Patents

二环酮化合物及其使用方法 Download PDF

Info

Publication number
CN110914271B
CN110914271B CN201880046714.2A CN201880046714A CN110914271B CN 110914271 B CN110914271 B CN 110914271B CN 201880046714 A CN201880046714 A CN 201880046714A CN 110914271 B CN110914271 B CN 110914271B
Authority
CN
China
Prior art keywords
dihydro
pyrrolo
triazol
phenyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880046714.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110914271A (zh
Inventor
斯纳赫尔·帕特尔
格雷戈里·汉密尔顿
赵桂玲
陈慧芬
布莱克·丹尼尔斯
克雷格·斯蒂瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202411725301.0A priority Critical patent/CN119613408A/zh
Publication of CN110914271A publication Critical patent/CN110914271A/zh
Application granted granted Critical
Publication of CN110914271B publication Critical patent/CN110914271B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CN201880046714.2A 2017-07-14 2018-07-12 二环酮化合物及其使用方法 Active CN110914271B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411725301.0A CN119613408A (zh) 2017-07-14 2018-07-12 二环酮化合物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762532767P 2017-07-14 2017-07-14
US62/532,767 2017-07-14
PCT/EP2018/068998 WO2019012063A1 (en) 2017-07-14 2018-07-12 BICYCLIC KETONIC COMPOUNDS AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411725301.0A Division CN119613408A (zh) 2017-07-14 2018-07-12 二环酮化合物及其使用方法

Publications (2)

Publication Number Publication Date
CN110914271A CN110914271A (zh) 2020-03-24
CN110914271B true CN110914271B (zh) 2024-12-10

Family

ID=62916677

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880046714.2A Active CN110914271B (zh) 2017-07-14 2018-07-12 二环酮化合物及其使用方法
CN202411725301.0A Pending CN119613408A (zh) 2017-07-14 2018-07-12 二环酮化合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411725301.0A Pending CN119613408A (zh) 2017-07-14 2018-07-12 二环酮化合物及其使用方法

Country Status (30)

Country Link
US (3) US11098058B2 (enExample)
EP (2) EP3652178B1 (enExample)
JP (2) JP7258843B2 (enExample)
KR (2) KR102664604B1 (enExample)
CN (2) CN110914271B (enExample)
AR (1) AR112274A1 (enExample)
AU (3) AU2018300043B2 (enExample)
BR (1) BR112020000771A2 (enExample)
CA (2) CA3067944C (enExample)
CL (1) CL2020000101A1 (enExample)
CO (1) CO2020000134A2 (enExample)
CR (1) CR20200002A (enExample)
DK (1) DK3652178T3 (enExample)
ES (1) ES2973661T3 (enExample)
FI (1) FI3652178T3 (enExample)
HR (1) HRP20240354T1 (enExample)
HU (1) HUE065793T2 (enExample)
IL (2) IL271981B (enExample)
LT (1) LT3652178T (enExample)
MA (1) MA49560B1 (enExample)
PE (1) PE20200793A1 (enExample)
PH (1) PH12020500105A1 (enExample)
PL (1) PL3652178T3 (enExample)
PT (1) PT3652178T (enExample)
RS (1) RS65308B1 (enExample)
SG (1) SG11202000333UA (enExample)
SI (1) SI3652178T1 (enExample)
TW (1) TWI805595B (enExample)
UA (1) UA125448C2 (enExample)
WO (1) WO2019012063A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110282A1 (es) * 2016-12-02 2019-03-13 Hoffmann La Roche Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR112274A1 (es) 2017-07-14 2019-10-09 Hoffmann La Roche Compuestos bicíclicos de cetona y sus métodos de uso
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
TW202043229A (zh) 2019-01-11 2020-12-01 瑞士商赫孚孟拉羅股份公司 雙環酮化合物及其使用方法
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
TWI879949B (zh) * 2020-04-27 2025-04-11 南韓商奧土擇破利悟股份有限公司 用於ｕｂｒ盒結構域配體之化合物、組成物以及醫藥組成物
CA3214802A1 (en) 2021-04-02 2022-10-06 Genentech, Inc. Processes for making bicyclic ketone compounds
WO2023039795A1 (zh) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Rip1激酶抑制剂及其用途
JP7680639B1 (ja) * 2022-05-19 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー Ｒｉｐｋ１阻害剤及び使用方法
WO2024260932A2 (en) * 2023-06-19 2024-12-26 F. Hoffmann-La Roche Ag Process for the preparation of a chiral pyrrolo triazole alcohol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121432A (zh) * 2013-02-15 2015-12-02 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的杂环酰胺
WO2017004500A1 (en) * 2015-07-02 2017-01-05 Genentech, Inc. Bicyclic lactams and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
US6653304B2 (en) * 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
KR101186210B1 (ko) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
DE602004016992D1 (de) 2003-05-02 2008-11-20 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
CA2605899C (en) 2005-04-26 2011-02-08 Pfizer Limited Triazole derivatives as vasopressin antagonists
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
ES2552514T3 (es) 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Compuestos bicíclicos de piperazina
BR112014026176A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche dipiridilaminas substituídas e usos das mesmas
CN104918934B (zh) 2013-01-18 2017-12-22 霍夫曼-拉罗奇有限公司 3‑取代的吡唑及其作为dlk抑制剂的用途
MX2015015130A (es) 2013-05-01 2016-02-18 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos.
EP2991977B1 (en) 2013-05-01 2020-07-22 F.Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
KR102306951B1 (ko) 2013-07-10 2021-10-01 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 융합된 피페리딘 아미드
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EP3182974A1 (en) 2014-08-21 2017-06-28 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2016128908A1 (en) * 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
EP3268373B1 (en) 2015-03-09 2022-04-27 F. Hoffmann-La Roche AG Tricyclic dlk inhibitors and uses thereof
US10709692B2 (en) 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
AR110282A1 (es) 2016-12-02 2019-03-13 Hoffmann La Roche Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3566471B1 (en) 2017-01-05 2022-09-28 Microsoft Technology Licensing, LLC Audio simulation in video games comprising indirect propagation paths
AR112274A1 (es) 2017-07-14 2019-10-09 Hoffmann La Roche Compuestos bicíclicos de cetona y sus métodos de uso
AU2018348930A1 (en) 2017-10-11 2020-03-26 F. Hoffmann-La Roche Ag Bicyclic compounds for use as RIP 1 kinase inhibitors
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121432A (zh) * 2013-02-15 2015-12-02 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的杂环酰胺
WO2017004500A1 (en) * 2015-07-02 2017-01-05 Genentech, Inc. Bicyclic lactams and methods of use thereof

Also Published As

Publication number Publication date
SI3652178T1 (sl) 2024-05-31
CA3067944C (en) 2023-03-14
LT3652178T (lt) 2024-04-10
RU2020106375A3 (enExample) 2022-03-25
KR20200030558A (ko) 2020-03-20
CL2020000101A1 (es) 2020-07-17
AU2023203292B2 (en) 2025-01-30
PT3652178T (pt) 2024-03-18
PE20200793A1 (es) 2020-08-10
US20210139504A1 (en) 2021-05-13
PL3652178T3 (pl) 2024-05-06
AR112274A1 (es) 2019-10-09
IL271981B (en) 2022-09-01
CA3185865A1 (en) 2019-01-17
MA49560B1 (fr) 2024-05-31
US11834461B2 (en) 2023-12-05
WO2019012063A1 (en) 2019-01-17
RU2020106375A (ru) 2021-08-16
JP7258843B2 (ja) 2023-04-17
PH12020500105A1 (en) 2020-11-09
MA49560A (fr) 2020-05-20
US11098058B2 (en) 2021-08-24
JP2020526549A (ja) 2020-08-31
RS65308B1 (sr) 2024-04-30
DK3652178T3 (da) 2024-03-25
KR102664604B1 (ko) 2024-05-14
EP3652178A1 (en) 2020-05-20
HRP20240354T1 (hr) 2024-06-07
EP4397309A2 (en) 2024-07-10
CA3067944A1 (en) 2019-01-17
SG11202000333UA (en) 2020-02-27
CO2020000134A2 (es) 2020-01-17
IL294961A (en) 2022-09-01
ES2973661T3 (es) 2024-06-21
TWI805595B (zh) 2023-06-21
IL271981A (en) 2020-02-27
HUE065793T2 (hu) 2024-06-28
CN119613408A (zh) 2025-03-14
EP4397309A3 (en) 2024-09-04
CN110914271A (zh) 2020-03-24
CR20200002A (es) 2020-02-10
AU2018300043A1 (en) 2020-01-16
FI3652178T3 (fi) 2024-03-19
UA125448C2 (uk) 2022-03-09
US20190100530A1 (en) 2019-04-04
AU2021204369A1 (en) 2021-07-29
JP2023085449A (ja) 2023-06-20
AU2023203292A1 (en) 2023-06-22
BR112020000771A2 (pt) 2020-07-14
NZ760749A (en) 2024-08-30
JP7734163B2 (ja) 2025-09-04
TW201920149A (zh) 2019-06-01
KR20240065201A (ko) 2024-05-14
EP3652178B1 (en) 2024-01-24
US20240300974A1 (en) 2024-09-12
AU2018300043B2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
CN110914271B (zh) 二环酮化合物及其使用方法
EP3781571B1 (en) N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
US11607396B2 (en) Bicyclic amide compounds and methods of use thereof
EP3694858B1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
US20250282788A1 (en) Bicyclic ketone compounds and methods of use thereof
RU2797922C2 (ru) Бициклические кетоны и способы их применения
HK40017913B (zh) 二环酮化合物及其使用方法
HK40017913A (en) Bicyclic ketone compounds and methods of use thereof
HK40036919A (en) Compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017913

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant